Human Abuse Potential of Single Oral Doses of Sunobinop, a Novel, Highly Potent, and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors

Key Points

• To assess the abuse potential and tolerability of the novel drug sunobinop compared to placebo and triazolam.
• Administered single oral doses of sunobinop, placebo, and triazolam.
• Compared drug-liking scores across all conditions.
• Evaluated tolerability profile in various populations.
• Sunobinop showed no significant difference in drug-liking compared to placebo.
• Drug-liking for sunobinop was significantly lower than that of triazolam.
• The tolerability profile for sunobinop was favorable, indicating potential for clinical use.